Changes in Hong Kong stocks | Le Méridien Vaccine (06660) once rose more than 25%, Serum-free Mad Vaccine Phase III blindness companies accelerated the listing of major single products

The Zhitong Finance App learned that the Hong Kong stock pharmaceutical sector rebounded strongly on the eve of the 11th National Day, and the Emmy vaccine (06660) continued to lead the rise. It once rose more than 25% in early trading today. As of press release, it rose 18.04% to HK$6.87, with a turnover of HK$87.7566 million.

According to the news, the Le Meridien vaccine announced that the company has completed decontamination and statistical analysis of phase III clinical trial data of the iterative serum-free vaccine. The results show that the vaccine has good immunogenicity and safety, and has reached the pre-set clinical goals. Up to now, there are no Serum-Free Maniacs on the market in the world. This product is expected to be the first product to be marketed, leading the deep iterative upgrading of technology in the industry.

According to reports, the iterative serum-free vaccine is completely different from the current Vero cell vaccine containing serum and the human diploid vaccine containing serum. Because it does not contain animal serum, it significantly improves safety, reduces the probability of adverse reactions, and makes vaccinators safer. It is a highly innovative iterative upgrade product.